Gene signature identifies leukemia patients who should avoid transplants

December 09, 2002

PHILADELPHIA -- An international team of researchers led by scientists at Dana-Farber Cancer Institute in Boston have used a gene test to identify certain patients with adult T-cell acute lymphoblastic leukemia (ALL) who can be successfully treated with chemotherapy alone and should not be subjected to the rigors of bone marrow transplants.

Adolfo Ferrando, MD, PhD, and A. Thomas Look, MD, of Dana-Farber, along with collaborators from several institutions in the United States and Israel, found that these patients survived for at least three years after being treated with intensive chemotherapy. The researchers will present their data at the annual meeting of the American Society of Hematology in Philadelphia (Dec. 9, 5 p.m., Room 114).

It was previously known that only slightly over half of the patients with this disease could be cured with chemotherapy. Adult ALL patients often undergo transplants in an effort to beat back the stubborn disease. Until now there was no way to identify those who have a more favorable outlook and shouldn't undergo risky bone marrow transplantation.

Earlier this year, these scientists, led by Look, reported in the journal Cancer Cell a detailed analysis of the genes involved in the pathogenesis of T-cell ALL measured using high-tech "gene chips" or microarrays.

"The microarray analysis shows that cases of T-cell ALL with expression of HOX11 behave in a very particular way," says Ferrando. "They have their own genetic program that creates a type of leukemia cell that's easier to kill with chemotherapy."

What distinguished the good-prognosis patients was having high activity of a gene called HOX11 in their leukemia cells; those with low HOX11 expression were much less likely to do as well.

The discovery of a gene test could be a major advance for the treatment of the adult T-cell ALL. According to Ferrando, it could ease the dilemma of which patients to treat with transplants and at what point in their disease. "Some say you should wait until a patient relapses [following a first remission achieved with drugs] to transplant, while others say you should transplant them early after achieving the first remission." And some patients don't need a transplant at all.

In the study, researchers obtained bone marrow samples from two groups of adult T-cell ALL patients - one group of 24 patients and another of 30. Of these 54 patients, 16 were found to have the HOX11 genotype. Forty-three of the patients received only chemotherapy and 11 had bone marrow transplants when they were in their first remission.

Four of the HOX11 patients died, three of them from transplant complications. All of the HOX11 patients treated with chemotherapy alone survived for three years, and were most likely cured, while only 53 percent of the patients lacking that gene activity survived for three years.

"Our results demonstrate that these patients with high HOX11 gene activity have an excellent prognosis when treated with intensive chemotherapy and should be spared the toxic effects and early death that can accompany the use of bone marrow transplantation in first remission," say the researchers.
-end-
Dana-Farber Cancer Institute (www.danafarber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

Dana-Farber Cancer Institute

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.